Video Blog

Cost-Savings Opportunities: Biosimilars

In this short video, we highlight actions you can take now to develop and implement strategies that will lead to higher adoption rates of less-costly Humira biosimilars.

With over $16 billion in sales in 2020, the biologic drug Humira (adalimumab) remains far and away the top-selling drug by dollars in the United States. A “patent thicket” of over 100 patents has thwarted competitor drugs from coming to market. But now, at least six Humira biosimilars will finally enter the market in 2023.